Results 151 to 160 of about 1,322 (181)

Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk

Biological Psychiatry, 2001
This study's goal was to characterize nursing infants' exposure to fluoxetine through breast milk and to identify variables for minimizing such exposure.Nursing women on stable daily doses of fluoxetine were recruited into the study. Breast milk, maternal and infant serum concentrations of fluoxetine and norfluoxetine were determined with high ...
V, Hendrick, Z N, Stowe, L L, Altshuler, J, Mintz, S, Hwang, A, Hostetter, R, Suri, K, Leight, A, Fukuchi   +8 more
openaire   +2 more sources

STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP

Drug Metabolism and Disposition, 2004
We examined the stereoselective disposition of fluoxetine (FX) and its metabolite norfluoxetine (NFX) in five pregnant sheep. Racemic FX was administered i.v. to the ewe (50 mg) and the fetus (10 mg) on separate occasions. Maternal and fetal blood, maternal urine, and fetal amniotic and tracheal fluid samples were collected for 72 h. FX and NFX isomers
John, Kim, K Wayne, Riggs, Dan W, Rurak
openaire   +2 more sources

Evaluation of a New Pepsin Enzyme Chiral Stationary Phase for the Optimized Separation of Seproxetine (S-Norfluoxetine) from R-Norfluoxetine

Journal of Liquid Chromatography & Related Technologies, 1996
Abstract A thorough analysis of a new commercially available pepsin chiral stationary phase (CSP) has been completed using seproxetine (S-norfluoxetine) hydrochloride bulk drug substance and R-norfluoxetine hydrochloride as the test analytes. Chromatographic properties of this new Ultron ES-Pepsin column were investigated by varying key mobile phase ...
Donald S. Risley, V. Scott Sharp, John R. Palmer   +2 more
openaire   +1 more source

Excretion of Fluoxetine and Its Metabolite, Norfluoxetine, in Human Breast Milk

The Journal of Clinical Pharmacology, 1996
A study was conducted to measure breast milk concentrations of fluoxetine and its active metabolite, norfluoxetine, excreted in breast milk in a cohort of nursing women using fluoxetine, and to estimate infant dose from nursing. The study included 10 women nursing 11 infants (median age, 185 days). The mean fluoxetine dose was 0.39 mg/kg/day.
A, Taddio, S, Ito, G, Koren
openaire   +2 more sources

Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine

Naunyn-Schmiedeberg's Archives of Pharmacology, 1996
Fluoxetine and its primary metabolite, norfluoxetine, are inhibitors of neuronal uptake of 5-hydroxytryptamine. While fluoxetine has also been reported to inhibit monoamine oxidase (MAO) in vitro at concentrations much lower than those measured in brain following chronic fluoxetine treatment, neurochemical profiles are not consistent with substantial ...
A, Holt, G B, Baker
openaire   +2 more sources

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study

American Journal of Psychiatry, 1997
Prior studies examining the relationship between fluoxetine plasma concentrations and response in major depression have either found no relationship between plasma concentration and response or suggested a curvilinear relationship with a therapeutic window.
J D, Amsterdam, J, Fawcett, F M, Quitkin, F W, Reimherr, J F, Rosenbaum, D, Michelson, M, Hornig-Rohan, C M, Beasley   +7 more
openaire   +2 more sources

Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration

American Journal of Psychiatry, 1992
In vivo 19fluorine nuclear magnetic resonance spectroscopy was used to measure the brain concentration of fluoxetine and norfluoxetine in five patients with obsessive-compulsive disorder and three with major depression. The mean brain:plasma ratio of the parent drug plus the metabolite was significantly elevated to 2.6 (SD = 1.0) (95% confidence ...
P F, Renshaw, A R, Guimaraes, M, Fava, J F, Rosenbaum, J D, Pearlman, J G, Flood, P R, Puopolo, K, Clancy, R G, Gonzalez   +8 more
openaire   +2 more sources

Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine

International Clinical Psychopharmacology, 1993
The relationship between plasma concentration, clinical outcome and side-effects was examined in 23 patients with major depressive disorder (DSM-III-R) treated with fluoxetine. All patients received a fixed dose of 20 mg for 6 weeks. Good response was observed in 57% of patients, while 30% of patients had moderate responses after 6 weeks of treatment ...
T R, Norman, R K, Gupta, G D, Burrows, G, Parker, F K, Judd   +4 more
openaire   +2 more sources

Improved HPLC determination of fluoxetine and norfluoxetine in human plasma

Chromatographia, 1999
An HPLC method with fluorescence detection has been developed for the determination of fluoxetine and its main metabolite norfluoxetine in human plasma. Pretreatment of the biological samples by liquid-liquid extraction was used to improve the sensitivity of a previously published SPE procedure.
M. A. Raggi, R. Mandrioli, G. Casamenti, V. Volterra, C. Desiderio, S. Fanali   +5 more
openaire   +1 more source

An asymmetric dihydroxylation route to enantiomerically pure norfluoxetine and fluoxetine

Tetrahedron Letters, 2002
An efficient, practical asymmetric synthesis of (R)-norfluoxetine 1 and (R)-fluoxetine 2 has been achieved. The synthetic strategy features a Sharpless asymmetric dihydroxylation (SAD) route to the common building block 1,3-amino alcohol 9, from which (R)-norfluoxetine, (R)-fluoxetine and other related analogs can be synthesized.
Rajesh Kumar Pandey, Rodney A. Fernandes, Pradeep Kumar   +2 more
openaire   +1 more source